Skip to content
Disclosery

JOHNSON & JOHNSON

Follow

13F filer, CIK 200406, NEW BRUNSWICK, NJ

JOHNSON & JOHNSON reported $652,355,946 across 16 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-13. Its ten largest share positions make up 98.99% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000904454-26-000280

Period
2026-03-31
Reported value
$652M
Holdings
16
Top 10 weight
98.99%
New
1
Sold out
2

Part of the filer group JOHNSON & JOHNSON

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RLYBnew+152,901$1.37M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RALLYBIO CORPexited-3,636,363-$2.49M
LYELexited-54,887-$1.69M
NNOXreduced-75,298-$171K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0000904454-26-000280, largest first. % of portfolio is the value over $652,355,946, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,449,183 shares; 2024Q4: 2,449,183 shares; 2025Q1: 2,449,183 shares; 2025Q2: 2,449,183 shares; 2025Q3: 2,449,183 shares; 2025Q4: 2,449,183 shares; 2026Q1: 2,449,183 shares 2,449,183$258M39.57%0Timeline
NBTXNANOBIOTIXQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 5,623,816 shares; 2024Q4: 5,623,816 shares; 2025Q1: 5,623,816 shares; 2025Q2: 5,623,816 shares; 2025Q3: 5,623,816 shares; 2025Q4: 5,623,816 shares; 2026Q1: 5,623,816 shares 5,623,816$174M26.61%0Timeline
MGTXMEIRAGTX HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 6,641,064 shares; 2024Q4: 6,641,064 shares; 2025Q1: 6,641,064 shares; 2025Q2: 6,641,064 shares; 2025Q3: 6,641,064 shares; 2025Q4: 6,641,064 shares; 2026Q1: 6,641,064 shares 6,641,064$57.5M8.82%0Timeline
RAPPRAPPORT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,498,051 shares; 2024Q4: 2,498,051 shares; 2025Q1: 2,498,051 shares; 2025Q2: 2,498,051 shares; 2025Q3: 1,784,517 shares; 2025Q4: 1,784,517 shares; 2026Q1: 1,784,517 shares 1,784,517$55.8M8.56%0Timeline
CVRXCVRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,103,430 shares; 2024Q4: 4,103,430 shares; 2025Q1: 4,103,430 shares; 2025Q2: 4,103,430 shares; 2025Q3: 4,103,430 shares; 2025Q4: 4,024,861 shares; 2026Q1: 4,024,861 shares 4,024,861$38.1M5.84%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,979,173 shares; 2024Q4: 1,979,173 shares; 2025Q1: 1,979,173 shares; 2025Q2: 1,979,173 shares; 2025Q3: 1,979,173 shares; 2025Q4: 1,979,173 shares; 2026Q1: 1,979,173 shares 1,979,173$25.8M3.96%0Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 814,586 shares; 2024Q4: 814,586 shares; 2025Q1: 814,586 shares; 2025Q2: 814,586 shares; 2025Q3: 814,586 shares; 2025Q4: 814,586 shares; 2026Q1: 814,586 shares 814,586$14.7M2.26%0Timeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 748,062 shares; 2024Q4: 748,062 shares; 2025Q1: 748,062 shares; 2025Q2: 748,062 shares; 2025Q3: 748,062 shares; 2025Q4: 748,062 shares; 2026Q1: 748,062 shares 748,062$9.02M1.38%0Timeline
PRCTPROCEPT BIOROBOTICS CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 357,939 shares; 2024Q4: 357,939 shares; 2025Q1: 357,939 shares; 2025Q2: 357,939 shares; 2025Q3: 357,939 shares; 2025Q4: 357,939 shares; 2026Q1: 357,939 shares 357,939$8.95M1.37%0Timeline
FATEFATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,379,064 shares; 2024Q4: 3,379,064 shares; 2025Q1: 3,379,064 shares; 2025Q2: 3,379,064 shares; 2025Q3: 3,379,064 shares; 2025Q4: 3,379,064 shares; 2026Q1: 3,379,064 shares 3,379,064$4.05M0.62%0Timeline
NMRANEUMORA THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,849,445 shares; 2024Q4: 1,849,445 shares; 2025Q1: 1,849,445 shares; 2025Q2: 1,849,445 shares; 2025Q3: 1,849,445 shares; 2025Q4: 1,849,445 shares; 2026Q1: 1,849,445 shares 1,849,445$3.61M0.55%0Timeline
RLYBRALLYBIO CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 152,901 shares 152,901$1.37M0.21%newTimeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 53,732 shares; 2026Q1: 53,732 shares 53,732$959K0.15%0Timeline
LABSTANDARD BIOTOOLS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 311,967 shares; 2024Q4: 311,967 shares; 2025Q1: 311,967 shares; 2025Q2: 311,967 shares; 2025Q3: 311,967 shares; 2025Q4: 311,967 shares; 2026Q1: 311,967 shares 311,967$287K0.04%0Timeline
NNOXNANO X IMAGING LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 158,852 shares; 2024Q4: 158,852 shares; 2025Q1: 158,852 shares; 2025Q2: 158,852 shares; 2025Q3: 158,852 shares; 2025Q4: 158,852 shares; 2026Q1: 83,554 shares 83,554$190K0.03%-75,298Timeline
ACETADICET BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 22,779 shares; 2026Q1: 22,779 shares 22,779$155K0.02%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RALLYBIO CORPRALLYBIO CORP3,636,363$2.49Mshares
LYELLYELL IMMUNOPHARMA INC54,887$1.69Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000904454-26-000280 base2026-05-13acceptance time not in the bulk data set